WNS Signs Contract Extension with Leading Pharmaceutical Company for High-End Research & Analytics Services
WNS (Holdings) Limited (NYSE: WNS), a leading provider of global
Business Process Outsourcing (BPO) services, announced today that it has
extended its contract with global pharmaceutical leader GlaxoSmithKline
Services Unlimited (GSK), to deliver high-end research and analytics
services.
"In a rapidly changing and increasingly competitive global economy, the
ability to analyze large amounts of complex data to drive insight-based
decisions is critical to success. WNS has been a trusted partner in
delivering these high-value analytics solutions to GSK, and we are
delighted to announce this contract extension with a recognized leader
in the pharmaceutical industry,” said Keshav R. Murugesh, Group CEO, WNS
Global Services.
WNS enables its global clients to make critical business decisions
leveraging its research and analytics expertise, deep industry knowledge
and robust delivery capabilities. WNS currently has over 2,000 research
and analytics professionals supporting areas such as customer lifecycle
analytics, market and business research, strategy and decision support,
demand forecasting, customer risk scoring, loss management modeling, and
measurement and reporting.
About WNS
WNS (Holdings)
Limited (NYSE: WNS), is a leading global business process outsourcing
company. WNS offers business value to 200+ global clients by combining
operational excellence with deep domain expertise in key industry
verticals including Travel, Insurance, Banking and Financial Services,
Manufacturing, Retail and Consumer Packaged Goods, Shipping and
Logistics and Healthcare and Utilities. WNS delivers an entire spectrum
of business process outsourcing services such as finance and accounting,
customer care, technology solutions, research and analytics and industry
specific back office and front office processes. As of March 31, 2013,
WNS had 25,520 professionals across 31 delivery centers worldwide
including Costa Rica, India, Philippines, Poland, Romania, South Africa,
Sri Lanka, United Kingdom and the United States. For more information,
visit www.wns.com.
Safe Harbor Statement
This
document includes information which may constitute forward-looking
statements made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, the accuracy of which are
necessarily subject to risks, uncertainties, and assumptions as to
future events. Factors that could cause actual results to differ
materially from those expressed or implied are discussed in our most
recent Form 20-F and other filings with the Securities and Exchange
Commission. WNS undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
